The short answer. PT-141 is bremelanotide, which FDA approved as Vyleesi on June 21, 2019. Because it is a component of an approved drug, a 503A pharmacy may compound it for a named patient, subject to the essentially-a-copy rules. As of September 25, 2026, research-labeled “PT-141 peptide” is a different matter entirely.
| FDA approved | Yes. Vyleesi (NDA 210557, Jun 21, 2019): premenopausal women with acquired, generalized hypoactive sexual desire disorder. Not for men or postmenopausal women. |
|---|---|
| 503A pharmacy | Eligible as a component of an approved drug, restricted by the essentially-a-copy rules. |
| 503B outsourcing facility | No pathway. |
| Latest FDA action | Warning letters to research-peptide sellers naming “PT-141 peptide”, Aug 24, 2026. |
| MDside position | Patient-specific from a 503A pharmacy, with any difference from Vyleesi documented on the prescription. |
| Last verified | 2026-09-25 |
Vendor tables that say “503A: No” are out of date
Before June 2019, bremelanotide had no approved-drug status, and FDA’s 2020 warning letter to Tailor Made Compounding, based on a 2018 inspection, treated it as ineligible. Approval changed that. A substance that is a component of an approved drug is eligible for 503A compounding without a nomination, which is why bremelanotide appears in no 503A category.
The copy rules are the real limit
Vyleesi is on the market, so a compounded bremelanotide injection at the same or a similar strength is presumptively essentially a copy. The same three tests apply as for semaglutide: the copy definition, a documented significant difference for the identified patient, and FDA’s policy of not acting at four or fewer copy prescriptions a month. FDA’s guidance treats a product for a different route as outside the copy definition, since the route is one of its elements.
Off-label is a prescriber decision, and it is a big one here
Vyleesi’s approval covers premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not approved for men or postmenopausal women, or to enhance sexual performance. Prescribing outside that is a clinical judgment the prescriber owns, and marketing it as an approved use is a misbranding problem.
What this means for you
If PT-141 is on your menu, source it from a 503A pharmacy for named patients, and have the prescriber document any difference from Vyleesi on the prescription. Drop research-labeled product. Check that your marketing does not describe uses beyond the approved indication as approved. Our hormone therapy program works this way.
Read next
Frequently asked questions
Is PT-141 FDA approved?
Yes, as bremelanotide under the brand Vyleesi, approved June 21, 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not approved for men or postmenopausal women. Research-labeled PT-141 is not the approved product, and FDA named it in warning letters to research-peptide sellers in August 2026.
Can PT-141 be compounded?
Yes, by a 503A pharmacy for a named patient, because bremelanotide is a component of an approved drug. Vyleesi is commercially available, so a similar injection is presumptively a copy unless the prescriber documents a significant difference, subject to FDA’s four-a-month enforcement policy.
Is PT-141 approved for men?
No. Vyleesi’s approval covers premenopausal women with acquired, generalized hypoactive sexual desire disorder only. Use in men is off-label, a clinical decision the prescriber owns, and it cannot be advertised as an approved use. It is also not approved for postmenopausal women or to enhance sexual performance.
Primary sources. Last verified September 25, 2026. Corrections are welcome: contact us.
- Drugs@FDA, Vyleesi (bremelanotide), NDA 210557
- FDA guidance, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (Jan 2018)
- FDA, 503A bulk drug substance categories (updated May 14, 2026)
- FDA warning letter, Tailor Made Compounding (Apr 1, 2020)
- FDA warning letter, NuScience Peptides (Aug 24, 2026)
- FDA warning letter, Royal Peptides (Aug 24, 2026)
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.